Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
Atopic dermatitis (AD) is a clinically heterogenous, inflammatory skin condition with a high impact on patients’ daily activities that remains difficult to treat. The knowledge acquired over the last decade on AD pathophysiology and disease burden led to the development of new targeted therapeutic...
Guardado en:
Autores principales: | Miguel Nogueira, Tiago Torres |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Mattioli1885
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f2263195ebd44087a6390424e7c41784 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Giulia Radi, et al.
Publicado: (2021) -
Baricitinib for the treatment of rheumatoid arthritis
por: Ivan Urits, et al.
Publicado: (2020) -
The role of interleukin-24 in atopic dermatitis
por: Yen Hai Vu, et al.
Publicado: (2021) -
Significance of food allergy in atopic dermatitis in children
por: O.P. Volosovets, et al.
Publicado: (2021) -
Atopic Dermatitis: Epidemiology and Clinical Phenotypes
por: Annunziata Raimondo, et al.
Publicado: (2021)